PRE-ANNOUNCEMENT: the information below is indicative and subject to change until the official call is published

The European Rare Diseases Research Alliance (ERDERA) has pre-announced its 2027 Joint Transnational Call, co-funded by the European Commission and participating national and regional funding organisations.

This call is expected to support collaborative research on recently identified rare diseases that currently receive limited research attention.

• Two-stage application procedure.
• Projects are expected to address at least one of the following areas:
  • Natural history studies and patient registries.
  • Identification and validation of biomarkers.
  • Development of computer-based, cellular or animal models.
  • Investigation of disease mechanisms.
• Patient partner involvement is expected from the proposal preparation stage.
• The call is expected to focus on generating foundational knowledge needed for future therapeutic development.
• Pre-clinical therapy development, diagnostic tool development and interventional treatment trials are expected to be out of scope.

Objective: To advance understanding of recently identified rare diseases and generate evidence that could support future therapeutic development.

• Eligible applicants are expected to include universities and research institutes, clinical and public health organisations, enterprises of all sizes, and patient advocacy organisations, subject to national and regional funding rules.
• Participation of small and medium-sized enterprises (SMEs) is encouraged where funding rules permit.
• Consortia are expected to include 3 to 6 eligible principal investigator partners from at least 3 participating countries.
• No more than 2 eligible partners per country.
• Seven-partner consortia must include one partner from an underrepresented country or one early-career researcher.
• Eight-partner consortia must include two partners from either or both categories.
• Patient partners do not count towards consortium size limits.
• Each consortium is expected to appoint an eligible coordinator from a participating funding country or region.
• Research partners must contribute substantially to at least one work package.
• The disease studied must have been first reported in peer-reviewed literature on or after 01 January 2010 and include an association with a suspected causative mechanism.
• Applicants must cite the original publication using a PubMed identifier or digital object identifier.
• The disease must be registered in Orphanet or evidence of a registration request must be provided.
• Projects may address one disease or a small group of closely related diseases provided all eligibility criteria are met.
• Preliminary participating countries/regions include: Austria, Belgium (French-speaking Community and Wallonia), Bulgaria, Canada, Czech Republic, Estonia, France, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland and Türkiye.
• Eligibility remains subject to national and regional funding rules and may change before launch.

In case of interest, please click on 'm'interessa' and we will contact you.